NCT06406465 2026-03-18
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
7 trialsNCT02595424 2025-12-29
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04325425 2025-09-30
FOLFIRINEC
Centre Hospitalier Universitaire Dijon
Phase 2 Recruiting
NCT04268121 2025-07-23
NEONEC
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT02695459 2021-04-20
Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
The Netherlands Cancer Institute
Phase 2 Unknown
NCT00353015 2012-08-02
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00178698 2011-03-03
FR-WB-TT/che
The University of Texas Health Science Center, Houston
Phase 2 Unknown